Pathologic complete response to combination therapy with enfortumab vedotin and pembrolizumab in a patient with metastatic ureteral cancer. // Asian Journal of Urology. – URL: https://www.sciencedirect.com/science/article/pii/S2214388226000469?dgcid=rss_sd_all
Pathologic complete response to combination therapy with enfortumab vedotin and pembrolizumab in a patient with metastatic ureteral cancer. Asian Journal of Urology. https://www.sciencedirect.com/science/article/pii/S2214388226000469?dgcid=rss_sd_all
“Pathologic complete response to combination therapy with enfortumab vedotin and pembrolizumab in a patient with metastatic ureteral cancer.” Asian Journal of Urology.
@article{article116459,
title = {Pathologic complete response to combination therapy with enfortumab vedotin and pembrolizumab in a patient with metastatic ureteral cancer},
journal = {Asian Journal of Urology},
url = {https://www.sciencedirect.com/science/article/pii/S2214388226000469?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...